Bloomberg Businessweek

Copyright: 2024 iHeartMedia, Inc. © Any use of this intellectual property for text and data mining or computational analysis including as training material for artificial intelligence systems is strictly prohibited without express written consent from iHeartMedia

Latest Episodes:

Government Shutdown Ripples Through Health Care Sector Nov 07, 2025

Show notes

Senate Democrats are again urging Republicans to negotiate extending enhanced Obamacare premium tax credits, buoyed by sweeping gubernatorial elections in Virginia, New Jersey and a mayor’s race in New York City. Following this week's elections, Sen. Bernie Sanders (I-VT) said lawmakers’ government shutdown fight should continue unless President Donald Trump and House Speaker Mike Johnson (R-LA) commit to extending the ACA credits.
Dr. Susan J. Blumenthal has served under four US presidents, having achieved the rank of Rear Admiral (Ret.) with the US Public Health Service, is a former Assistant Surgeon General, and was the nation's first-ever Deputy Assistant Secretary for Women's Health. She currently works as a visiting professor with the MIT Media Lab. Dr. Blumenthal examines the impact of the ongoing government shutdown on the nation's millions of health-benefit recipients, and also details some of her advanced research on key issues affecting women's health -- particularly breast cancer. Dr. Blumenthal speaks with Norah Mulinda and Bailey Lipschultz on Bloomberg Businessweek Daily.

See omnystudio.com/listener for privacy information.

Schwab Agrees to Buy Private Share Platform for $660 Million Nov 06, 2025

Show notes

Watch Carol and Tim LIVE every day on YouTube: http://bit.ly/3vTiACF.
Charles Schwab Corp. agreed to buy Forge Global Holdings Inc., a marketplace for buying and selling shares of private companies, for about $660 million.
Under the terms of the transaction, Schwab will acquire all of Forge’s shares for $45 apiece, according a statement Thursday. That’s about 72% more than the closing price on Wednesday.
The deal would be the first for Schwab under Chief Executive Officer Rick Wurster, who took the helm of the retail brokerage at the beginning of the year. Acquiring Forge could aid his ambition to give customers more opportunities to gain exposure to unlisted companies, especially as those firms stay private for longer.
Westlake, Texas-based Schwab, which is also a bank, was swept up in the regional banking turmoil of 2023, but has since rebounded, reporting third-quarter earnings last month that beat estimates as consumers flocked to investing. Wurster said at the time that new Schwab brokerage accounts topped 1 million for the fourth quarter in a row.
Today's show features:

Rick Wurster, President & CEO of Charles Schwab on his firm agreeing to buy Forge Global Holdings
Kevin Gordon, Head of Macro Research and Strategy, Schwab Center for Financial Research on the challenges of investing amid the US government shutdown
Cayla Culver, Head of Risk & Controls, Schwab Advisor Services, on regulatory risks in the financial sector
Mike Townsend, Managing Director, Legislative & Regulatory Affairs, Charles Schwab, on evaluating political risks in the financial world on behalf of clients

See omnystudio.com/listener for privacy information.

Teva Surges After Push Into Branded Drugs Drives Sales Beat Nov 06, 2025

Show notes

Teva Pharmaceuticals Inc. surged after sales of branded medications topped expectations, showing that its strategy to expand into that drug category is working. Total revenue last quarter of $4.48 billion beat consensus, driven by a 33% gain for a group of drugs that includes Austedo. Meanwhile, sales of generics — Teva’s core business — missed estimates. The Tel Aviv, Israel-based company has pushed into branded medications that have been drivers of the company’s growth in recent years. The generics business continues to make up the majority of Teva’s revenue.
Richard Francis, Teva's President and CEO, discusses his company's growth strategy and its move to renew the sale process for its active ingredients business after talks with an unnamed buyer fell through. Richard speaks with Emily Graffeo and Katie Greifeld on Bloomberg Businessweek Daily.

See omnystudio.com/listener for privacy information.

Stocks Stage Rebound as Dip Buyers Wade Back In: Markets Wrap Nov 05, 2025

Show notes

Watch Carol and Tim LIVE every day on YouTube: http://bit.ly/3vTiACF.
At a time when every dip in stocks is perceived as an opportunity, buyers emerged after a brief pullback led by some of the biggest winners of the artificial-intelligence boom. Bitcoin rallied. Bonds fell.
Equities rebounded, with the S&P 500 up almost 1% following a slide that underscored worries over how stretched the market has become and how sensitive it is to unfavorable news. Chipmakers, which bore the brunt of the recent selling, led gains on Wednesday.
Bonds slid as data showed US services activity expanded at the fastest pace in eight months. Federal Reserve Governor Stephen Miran said a report underscoring a rise in employment at companies was “a welcome surprise,” but reiterated rates need to be lower.
Today's show features:

Rick Wurster, President & CEO of Charles Schwab on Advisor Services as a critical driver of Schwab’s business growth
Liz Ann Sonders, Chief Investment Strategist at Charles Schwab, on the market outlook for the remainder of 2025
Omar Aguilar, CEO & CIO of Schwab Asset Management on whether a resilient US economy is poised for a downturn
Kathy Jones, Chief Fixed Income Strategist. Charles Schwab, on US interest rate outlook and the Federal Reserve

See omnystudio.com/listener for privacy information.

The Race for the World's First Advanced Nuclear Microreactor Developer Nov 05, 2025

Show notes

NANO Nuclear Energy is a leading advanced nuclear energy and micro modular reactor technology company focused on developing clean energy solutions. Last month, the firm announced that it would be investing more than $12 million to establish a manufacturing and research and development facility in Illinois, with support from a state incentive program. It is expected to support nuclear engineers, component manufacturers, researchers, and support personnel who will work in collaboration with the University of Illinois Urbana-Champaign on NANO Nuclear's lead project, the KRONOS micro modular reactor (MMR) Energy System.

James Walker, the firm's CEO and director, discusses the pursuit of bringing the first functioning small modular reactor into operation. James speaks with Carol Massar and Tim Stenovec on Bloomberg Businessweek Daily. He is joined by Will Wade, Bloomberg News Energy Reporter.

See omnystudio.com/listener for privacy information.

Stock Bulls Get Wake-Up Call From Wall Street CEOs Nov 04, 2025

Show notes

Watch Bloomberg Businessweek Daily LIVE every day on YouTube: http://bit.ly/3vTiACF.
Risky assets slid, with tech stocks and cryptocurrencies bearing the brunt of the selling, after long-simmering concerns about lofty valuations were fanned anew by a chorus of Wall Street executives who warned investors to brace for a pullback.
With the rally confined to fewer and fewer shares as sentiment and technical indicators show signs of overheating, the chiefs of giants from Capital Group to Goldman Sachs Group Inc. and Morgan Stanley noted the possibility of a pullback as a healthy development.
Nobody needs to look hard to find warnings that stocks look frothy after a record-breaking surge from April’s nadir pushed valuations to levels associated with exuberance. Optimism has grown heated in recent months, with many traders seeming too busy chasing the upside to worry about an expensive market.
The S&P 500 recently notched one of its best six-month stretches since the 1950s fueled by the resilience of Corporate America, the booming outlook for artificial intelligence and hopes the Federal Reserve will keep cutting rates to prop up the economy. Yet those solid gains combined with the recent narrowness of the advance spurred vulnerability worries.
Today's show features:

Bloomberg Intelligence Global Equity Strategist Gillian Wolff on Tuesday’s tech-lead stock selloff
Kathy Wylde, President and CEO of the Partnership for New York City, on the 2025 NYC Mayoral Election
Mark Dixon, Founder & CEO of International Workplace Group, on earnings and the commercial real estate market
Bloomberg News Cross-Asset Reporter Isabelle Lee on new market entrants reshaping the $13 trillion ETF industry

See omnystudio.com/listener for privacy information.

Building Pharmaceutical Supply-Chain Resilience Nov 04, 2025

Show notes

Antheia is the next-generation pharmaceutical ingredient producer with a mission to end drug shortages. Using advanced biosynthesis and fermentation technology, Antheia’s biomanufacturing platform enables rapid, efficient, agile, and on-demand production of key starting materials (KSMs) and active pharmaceutical ingredients (APIs) that are critical to public health. The firm believes its flexible approach supports the needs of a growing society and improves global access to essential medicines.

Founded in 2015, Antheia has grown into a commercial-stage company with its first product to market, an active customer pipeline, and near-term product launches. Dr. Christina Smolke, the company's co-founder and CEO, details her company's value proposition with Carol Massar and Tim Stenovec on Bloomberg Businessweek Daily.

See omnystudio.com/listener for privacy information.

Palantir Reports Record Quarterly Revenue, Hikes Forecasts Nov 03, 2025

Show notes

Watch Carol and Tim LIVE every day on YouTube: http://bit.ly/3vTiACF.

Palantir Technologies Inc. raised its annual revenue outlook to $4.4 billion and outpaced analyst estimates for third-quarter sales, citing “accelerating and otherworldly” growth for its artificial intelligence and data analytics products.

Revenue increased 63% to $1.18 billion in the period ended in September, the company said Monday in a statement. Analysts, on average, estimated $1.09 billion. In the current quarter, sales will be about $1.33 billion, compared with an average projection of $1.19 billion.

Palantir has reported revenue above analyst estimates for 21 consecutive quarters, according to data compiled by Bloomberg.
“We are in a nosebleed zone,” Palantir Chief Executive Officer Alex Karp said in an interview Monday. “No one else is here.”
Profit, excluding some items, was 21 cents a share, compared with analysts’ average estimate of 17 cents.

Palantir has been one of the biggest public beneficiaries of the artificial intelligence boom. The company sells its AI software to both governments and companies, and has become a key provider to the US and its allies.

Founded in 2003 with backing from Peter Thiel and the venture arm of the CIA, Palantir’s software organizes information from disparate data sources and prompts customers to make better decisions, using AI tools to make those calls more quickly. In corporate settings, this can mean finding ways to save money. On the battlefield this can mean shortening the time from identifying a threat to neutralizing it.

Today's show features:

Bloomberg Businessweek Senior Reporter Max Chafkin with reaction to quarterly earnings from Palantir
Megan Horneman, Chief Investment Officer at Verdence Capital Advisors, on whether investors are facing a bubble amid continued bets on big tech and artificial intelligence
Bloomberg News Consumer Reporter Redd Brown with US IPO and Deals Reporter Ryan Gould on Kimberly-Clark agreeing to buy Tylenol-maker Kenvue for $40 billion
Adam Goldstein, Founder and CEO of Archer Aviation on next-generation transportation and the economic opportunities afforded by eVTOLs

See omnystudio.com/listener for privacy information.

The Fight Against Alzheimer’s Disease Nov 03, 2025

Show notes

Fanny Elahi, MD, PhD is a physician-scientist and Associate Professor in the Departments of Neurology, Neuroscience, and Pathology at the Icahn School of Medicine at Mount Sinai in New York City. She serves as Director of Fluid Biomarker Research at the Barbara and Maurice Deane Center for Wellness and Cognitive Health and is one of the leaders at the Alzheimer’s Disease Research Center, where she co-directs the Genetics and Genomics Core and oversees the development of novel blood biomarkers for neurodegenerative diseases.
Dr. Elahi discusses her critical work and the potential for using blood biomarkers as indicators for the eventual onset of brain disease, particularly in women. She speaks with Carol Massar and Tim Stenovec on Bloomberg Businessweek Daily.

See omnystudio.com/listener for privacy information.

Bloomberg Businessweek Weekend - October 31st, 2025 Oct 31, 2025

Show notes

Featuring some of our favorite conversations of the week from our daily radio show "Bloomberg Businessweek Daily."
Hosted by Carol Massar and Tim Stenovec
Hear the show live at 2PM ET on WBBR 1130 AM New York, Bloomberg 92.9 FM Boston, WDCH 99.1 FM in Washington D.C. Metro, Sirius/XM channel 121, on the Bloomberg Business App, Radio.com, the iHeartRadio app and at Bloomberg.com/audio.
You can also watch Bloomberg Businessweek on YouTube - just search for Bloomberg Global News.
Like us at Bloomberg Radio on Facebook and follow us on Twitter @carolmassar @timsteno and @BW

See omnystudio.com/listener for privacy information.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected